Prognostic significance of serum anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma
10.3760/cma.j.issn.1003-9279.2013.02.012
- VernacularTitle:血清EB病毒抗体水平与鼻咽癌患者预后的关系
- Keywords:
Nasopharyngeal neoplasms;
Herpesvirus 4,human;
Antibodies,viral;
Prognosis
- From:
Chinese Journal of Experimental and Clinical Virology
2013;27(2):119-122
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study was aimed to investigate the association between serum against Epstein-Barr virus (EBV) antibodies levels and nasopharyngeal carcinoma (NPC) patients' prognosis.Methods Blood samples from 140 primary NPC patients without metastasis were collected before and after treatment.The titers of VCA/IgA and EA/IgA were detected by immunoenzyme assay,and the levels of NA1/IgA and Rta/IgG were detected by enzyme-linked immunosorbent assay (ELISA).All patients received consequent follow-up and long-term efficacy and survival assessment.Results Post-treatment serum levels of VCA/IgA,EA/IgA,NA1/IgA and Rta/IgG in NPC patients significantly decreased than those before treatment,while had significantly higher than those in control individuals (P ＜ 0.05).Patients in remission had significantly lower pre-treatment serum levels of VCA/IgA and EA/IgA than patients with progression (P ＜ 0.05).None of serum levels of VCA/IgA,EA/IgA,NA1/IgA and Rta/IgG was associated with the 3-year overall survival (P ＞ 0.05).The progression-free survivals were significantly lower in patients with higher pre-treatment VCA/IgA (≥ 1∶320) and EA/IgA (≥ 1∶ 80) levels than in those with lower VCA/IgA (＜ 1∶ 320) and EA/IgA (＜ 1∶ 80) levels,respectively (61.8％ vs.86.5％,61.3％ vs.86.5％,P ＜ 0.001).Cox regression model analysis demonstrated that pre-treatment serum VCA/IgA level was an independent risk factor for progression-free survival (HR =3.80,P =0.001).Conclusion Anti-EBV VCA/IgA and EA/IgA might provide information regarding the prognosis of NPC patients.
